Breast disorder

This phase II trial tests a DNA-based vaccine called STEMVAC in 33 people with early-stage triple negative breast cancer (stages IB-III). The vaccine is designed to train the immune system to recognize and attack cancer cells that express certain proteins. Participants also recei…

This early-stage study tests whether a DNA vaccine that targets a protein called mammaglobin-A (found on many breast cancer cells) is safe for people with ER+, HER2- breast cancer. The vaccine is given alongside standard hormone therapy or chemotherapy before surgery. The study i…

This phase III trial tests whether adding pembrolizumab (Keytruda) after standard chemotherapy can help prevent triple-negative breast cancer from coming back. Over 1,100 patients with residual cancer after chemo are randomly assigned to receive pembrolizumab or placebo. The stud…

This study is for people with inflammatory breast cancer, a rare and aggressive type, who have already had chemotherapy and surgery. It tests whether adding the drug olaparib to standard radiation therapy helps keep the cancer from coming back. About 300 participants will be rand…

This study tests whether a newer drug, Z-Endoxifen, works better than the standard tamoxifen for postmenopausal women with advanced ER+/HER2- breast cancer. About 81 participants will receive one of the two hormone therapies to see which delays cancer growth longer. The goal is t…

This large phase 3 trial studied over 10,000 women with early-stage, hormone-receptor-positive breast cancer that hasn't spread to lymph nodes. It used the Oncotype DX test to assign women to hormone therapy alone or hormone therapy plus chemotherapy based on their recurrence sco…

This study tests two drugs together—disitamab vedotin and tucatinib—in people with advanced breast or stomach cancers that have a protein called HER2. The goal is to see if the combination is safe and shrinks tumors. About 172 participants will take part.

This study looks at how well oral vinorelbine, a chemotherapy pill, works in women with advanced breast cancer. It includes women who have already taken the drug or are starting it now. Researchers track how long the cancer stays under control and how patients feel during treatme…

This Phase 2 study tests whether adding another drug (ceralasertib or adavosertib) to the standard drug olaparib works better than olaparib alone for people with metastatic triple-negative breast cancer. The trial includes 273 adults whose cancer has specific genetic changes. One…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This phase III trial compares low-dose tamoxifen to standard hormone therapy (aromatase inhibitors) in postmenopausal women with low-risk, hormone-positive, HER2-negative early breast cancer. The goal is to see if the lower dose works just as well to prevent cancer from coming ba…

This large phase 3 trial studied over 5,000 women with hormone receptor-positive, HER2-negative breast cancer that had spread to 1-3 lymph nodes. Participants received standard hormone therapy (tamoxifen or an aromatase inhibitor) either alone or with chemotherapy. The goal was t…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests whether giving two immunotherapy drugs (decitabine and pembrolizumab) before standard chemotherapy can help the immune system attack HER2-negative breast cancer more effectively. About 46 adults with locally advanced disease will receive a short course of these d…

This early-stage study is testing a new drug, AB801, alone or with other treatments, in about 91 people with advanced cancers (like lung, colon, or breast cancer) that have not responded to standard therapies. The main goal is to check the drug's safety and find the best dose for…

This study is for women with a low-risk type of breast cancer that has spread to nearby lymph nodes or is T3N0. It compares standard care (which includes radiation to the lymph node area) against skipping that extra radiation. The goal is to see if avoiding regional radiation wor…

This phase 3 trial compares a new drug, SHR-A1811, to the standard treatment T-DM1 in women with HER2-positive breast cancer who still have cancer cells after initial therapy. The goal is to see if SHR-A1811 can better prevent the cancer from coming back. Participants receive eit…

This study tests a new drug called BNT327, given with chemotherapy, for people with advanced triple-negative breast cancer that has spread. The goal is to see if the combination is safe and shrinks tumors. About 83 adults will take part, and the study is currently active but not …

This phase 2 trial tests whether a vaccine made from a protein found on many triple-negative breast cancer cells can help prevent the cancer from coming back. Participants receive the vaccine along with an immune booster and a low dose of chemotherapy. The study includes women wi…

This pilot trial investigates whether hydroxychloroquine (a malaria drug) and everolimus (an immune-suppressing drug), taken alone or together, can help prevent breast cancer from returning in high-risk patients. The study enrolls people who have completed primary treatment for s…

This phase 2 trial tests whether giving radiation once a day for five days (instead of every other day) can keep the breast looking good after treatment. It includes 48 women aged 40 or older with low-risk, hormone-sensitive breast cancer. The goal is to see if this shorter sched…

This study is for people with HER2-positive stage II to IIIa breast cancer whose tumors completely disappear after initial chemotherapy and targeted therapy before surgery. The goal is to see if using fewer chemotherapy drugs after surgery can still keep the cancer from coming ba…

This phase 2 trial investigates whether adding the targeted drug palbociclib to standard endocrine therapy (letrozole or tamoxifen) improves tumor shrinkage before surgery in people with hormone receptor positive, HER2 negative breast cancer. The study includes both invasive lobu…

This Phase 3 study tests whether a new drug, inavolisib, combined with fulvestrant works better than the current standard alpelisib plus fulvestrant for people with a specific type of advanced breast cancer (HR-positive, HER2-negative, with a PIK3CA mutation). The trial enrolled …

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This early-stage trial tests a new drug called remzistotug, alone or with other cancer drugs, in 152 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is not yet known if the drug will sh…

This study tests whether taking enzalutamide for one year after standard treatment is practical for people with early-stage triple negative breast cancer that has androgen receptors. About 50 participants will take the drug and report on their quality of life. The main goal is to…

This early-stage trial tests a new approach for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. It combines a radioactive drug (lutetium NeoB) that targets cancer cells with a standard chemotherapy pill (capecitabi…

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab/pertuzumab or T-DM1) can prevent new or worsening brain metastases in people with advanced HER2+ breast cancer. About 48 participants who have stable disease elsewhere but a new brain tumor will r…

This early-phase trial is testing a new combination of drugs for people with a specific type of advanced breast cancer (ER+/HER2-) that has stopped responding to hormone therapy. The experimental treatment includes a radioactive drug (lutetium NeoB) that targets cancer cells, plu…

This study compares two modern, wire-free methods for locating non-palpable breast lesions before surgery: radioguided occult lesion localization (ROLL) using a radioactive tracer, and magnetic seed localization. The goal is to see which technique more reliably achieves clear sur…

This study looks at giving a single dose of radiation directly to the tumor site during breast-conserving surgery in women aged 60 and older with early-stage, hormone-sensitive breast cancer. The goal is to see if this shorter, targeted approach controls the cancer as well as sta…

This study offers continued access to the targeted cancer drug ribociclib for people with metastatic breast cancer who are already benefiting from it in a previous Novartis trial. About 134 participants will keep taking ribociclib, sometimes with other hormone therapies, while re…

This study tests whether adding belzutifan to fulvestrant can slow or stop the growth of a certain type of advanced breast cancer (ER+/HER2-) that has worsened despite hormone therapy. About 120 adults with inoperable or metastatic disease will receive either the new combination …

This phase I trial is testing a new drug called ASTX727 (a combination of decitabine and cedazuridine) alongside standard chemotherapy (paclitaxel) and immunotherapy (pembrolizumab) for people with metastatic triple-negative breast cancer that cannot be removed by surgery. The st…

This phase 2 trial is testing how well older adults (60+) with advanced HER2+ breast cancer tolerate a combination of two targeted drugs: lapatinib and trastuzumab. The study enrolled 40 participants and focuses on side effects, especially heart-related issues and severe toxiciti…

This study tests an experimental drug, imlunestrant, in people with advanced or metastatic breast cancer that is estrogen-receptor positive (ER+), as well as certain other cancers like endometrial cancer. The drug is given alone or combined with other anticancer therapies. The ma…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This early-stage trial tests a new antibody, BAY 3375968, designed to help the immune system fight advanced solid tumors. It works by reducing regulatory T cells that can suppress immune activity. The study will test the drug alone and combined with pembrolizumab in about 129 peo…

This was a planned early-stage trial to test a new oral drug called ERW316, alone or with hormone therapies, in people with advanced breast cancer or other solid tumors. The study aimed to find a safe dose and check for side effects. However, the trial was withdrawn before any pa…

This early-stage trial tests the safety and best dose of two oral drugs, ZEN003694 and binimetinib, taken together. It is for people with advanced solid tumors that have RAS pathway changes or triple-negative breast cancer that has spread or cannot be removed. The goal is to find…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This study tests whether losartan, a drug already used for high blood pressure, can reduce scarring (fibrosis) caused by radiation therapy in breast cancer patients. 43 women who had breast surgery and need radiation will receive either losartan or a placebo. Researchers will mea…

This early-stage study tests whether a mix of immune-boosting drugs and targeted radiation can help the body fight advanced solid tumors that cannot be removed by surgery. About 14 adults with certain types of skin cancer, sarcoma, or breast cancer will receive the treatment dire…

This study tests a combination of two drugs, cediranib and olaparib, in people with advanced solid tumors that have spread or cannot be removed by surgery. The cancers include certain types of breast, lung, and pancreatic cancer. The goal is to see if the combination can shrink t…

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This early-phase study tests a cancer vaccine (PVX-410) alone or with the immunotherapy drug pembrolizumab in 20 women with metastatic triple negative breast cancer who have a specific genetic marker (HLA-A2). The goal is to see if the vaccine safely boosts the immune system to f…

This early-phase study tests whether adding the drug niraparib to standard radiation therapy after surgery can help prevent triple negative breast cancer from coming back. Niraparib is a PARP inhibitor that blocks cancer cells from repairing their DNA. The study includes 21 adult…

This early-phase trial is testing a combination of two drugs—trastuzumab deruxtecan (a targeted chemotherapy) and ceralasertib (a drug that may block cancer cell repair)—in people with advanced solid tumors that have a HER2 mutation. The study has two parts: first, finding the sa…

This study compares a 1-week radiation course to a standard 3-week course for women with node-positive breast cancer. The goal is to see if the shorter treatment is just as effective at preventing cancer from coming back while reducing the risk of lymphedema (arm swelling). About…

This phase 2 trial is testing a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 798 people with over 50 types of rare cancers. The goal is to see if these drugs can shrink tumors by helping the immune system attack cancer cells. Participants receive the drugs…

This large Phase 3 study tests a new drug, giredestrant, against standard hormone therapies in about 4,170 people with early-stage, hormone-sensitive breast cancer. The goal is to see if giredestrant is better at preventing the cancer from returning after initial treatment. Parti…

This study is testing whether women over 55 with a specific low-risk type of breast cancer (luminal A) can avoid radiation after lumpectomy. Instead, they take hormone-blocking pills for 5 years. Researchers are tracking 500 women for 10 years to see how many have the cancer come…

This study tests a new drug called giredestrant in people with a type of advanced breast cancer (ER-positive, HER2-negative) that has progressed after prior treatments. About 303 participants will receive either giredestrant or another standard hormone therapy chosen by their doc…

This early-phase study tests a new drug called BG-68501 in people with advanced solid tumors that have not responded to standard treatments. The drug targets a protein (CDK2) that helps cancer cells grow. The trial will check safety, find the right dose, and see if the drug shrin…

This study tests whether combining two drugs (niraparib and dostarlimab) with radiation therapy is safe and effective for people with metastatic triple-negative breast cancer that has not responded to immunotherapy or is PD-L1 negative. About 32 adults with this aggressive cancer…

This early-phase study tests the safety of giving specially grown immune cells (T cells) to people with metastatic HER2-positive breast cancer. Participants first receive a vaccine made from their own immune cells plus two drugs (pepinemab and trastuzumab) to help the body fight …

This study tests a new drug, giredestrant, combined with everolimus against standard hormone therapy plus everolimus in people with a common type of advanced breast cancer (ER+/HER2-). About 373 participants who have already tried other treatments will be enrolled. The goal is to…

This phase 2 trial investigates whether a program of regular walking and a plant-based diet can lower aromatase levels in overweight postmenopausal women with hormone receptor-positive breast cancer who are already taking an aromatase inhibitor. Participants are randomly assigned…

This Phase 3 trial tests whether a new drug, datopotamab deruxtecan (Dato-DXd), given alone or with another drug (durvalumab), can help prevent breast cancer from returning in people with triple-negative breast cancer who still have cancer cells after initial treatment and surger…

This study tests a shorter course of radiation (hypofractionated) to the breast and nearby lymph nodes in 137 women with node-positive breast cancer. The goal is to see if this approach reduces arm swelling (lymphedema) and other side effects while still preventing cancer from co…

This study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…

This study tests an experimental drug called enfortumab vedotin in 329 adults with advanced solid tumors that have spread. The main goal is to see if the drug shrinks tumors. Researchers also check how long the effect lasts and monitor side effects. Some participants also receive…

This study tests whether adding the experimental drug inavolisib to two standard treatments (palbociclib and fulvestrant) can slow cancer growth in people with a specific genetic mutation (PIK3CA) in hormone receptor-positive, HER2-negative advanced breast cancer. About 325 parti…

This early-phase trial tests two different drug combinations—olaparib plus vistusertib, or olaparib plus capivasertib—in people with recurrent endometrial, triple-negative breast, ovarian, primary peritoneal, or fallopian tube cancer. The main goal is to find the safest dose and …

This phase 3 study tests whether adding alpelisib (a targeted pill) to fulvestrant (a hormone-blocking shot) can slow cancer growth in men and postmenopausal women with HR-positive, HER2-negative advanced breast cancer that has a PIK3CA mutation. Participants must have already tr…

This phase III trial tests whether adding tucatinib to standard T-DM1 therapy works better than T-DM1 alone at preventing breast cancer from coming back. It involves over 1,000 patients with HER2-positive breast cancer who still have cancer cells after initial treatment. The stud…

This early-stage trial is testing whether focused ultrasound (sound waves aimed at tumors) combined with a low dose of the chemotherapy drug gemcitabine can boost the immune system's ability to fight early breast cancer. About 32 participants will receive either ultrasound, low-d…

This study tested a new oral drug, AZD9833, against a standard injected treatment (fulvestrant) in 240 women with advanced ER-positive, HER2-negative breast cancer. The main goal was to see how long the cancer stayed under control. Results from one dose group were limited because…

This study tested whether adding the drug palbociclib for two years to standard hormone therapy (taken for at least five years) helps prevent breast cancer from coming back in people with early-stage HR+/HER2- breast cancer. About 5,800 participants with stage II or III cancer to…

This study looks at whether patients with early-stage HER2-positive breast cancer who have a complete response to initial chemotherapy and HER2-targeted therapy can safely receive only 6 months of further HER2 treatment instead of the standard 12 months. The goal is to reduce hea…

This study tests a combination of two drugs, eribulin and copanlisib, in people with metastatic triple-negative breast cancer that has spread or cannot be removed. The goal is to find the safest dose and see if the combo can slow tumor growth better than eribulin alone. About 24 …

This phase 2 trial tests a new immunotherapy drug called tobemstomig combined with chemotherapy (nab-paclitaxel) against the standard combination of pembrolizumab plus chemotherapy. It includes 83 people with previously untreated, PD-L1-positive, advanced triple-negative breast c…

This phase 2 trial tests whether adding an oral targeted drug called anlotinib to standard chemotherapy can better clear cancer from the breast and lymph nodes before surgery in people with early-stage HER2-negative breast cancer. The study enrolled 31 high-risk patients. The mai…

This study offers continued treatment with the drug olaparib to people with ovarian or breast cancer who have already seen benefits from it in a previous study. The goal is to keep providing the drug safely while monitoring for any serious side effects. About 185 participants wil…

This Phase 3 study tests whether adding the targeted drug alpelisib to standard maintenance therapy (trastuzumab and pertuzumab) can help people with advanced HER2-positive breast cancer that has a specific genetic change (PIK3CA mutation) live longer without their cancer growing…

This phase II study tests whether adding alpelisib (a targeted pill) to standard fulvestrant (a hormone-blocking shot) can delay cancer growth in Chinese men and postmenopausal women with a specific type of advanced breast cancer (HR+, HER2-, with a PIK3CA mutation) that has wors…

This early-phase study tests a new drug called RNDO-564, alone or with pembrolizumab, in adults with advanced solid tumors (like bladder, lung, or breast cancer) that have stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see i…

This study tests whether an integrative oncology program—including diet changes, exercise, stress management, social support, and reducing exposure to environmental toxins—can improve outcomes for women with stage II or III breast cancer undergoing radiation therapy. About 110 pa…

This study tests a combination of two drugs—alpelisib (a targeted therapy) and fulvestrant (a hormone blocker)—in Japanese men and postmenopausal women with a specific type of advanced breast cancer (HR+/HER2-) that has a PIK3CA mutation. The cancer must have worsened after prior…

This early-phase study tests a new drug called inavolisib in people with advanced solid tumors or breast cancer that have a specific PIK3CA gene mutation. The study aims to find a safe dose and see how well the drug works alone or with other cancer treatments. About 200 participa…

This study tests a combination of two experimental drugs (LEE011 and BYL719) plus a standard hormone therapy (letrozole) in about 255 women with advanced ER+ breast cancer. The goal is to find safe doses and see if the triple combination can better control the cancer. Participant…

This study tests a drug called elacestrant combined with other medicines in people with a common type of advanced breast cancer (ER+/HER2-). The goal is to find safe doses and see if these combinations can slow down cancer growth. About 435 adults with metastatic breast cancer wi…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This study tested whether a higher dose (500 mg) of the drug fulvestrant works better than the standard dose (250 mg) in postmenopausal women with a certain type of advanced breast cancer that had worsened after previous hormone therapy. The trial involved 736 participants and me…

This phase II trial tests whether combining an immunotherapy (atezolizumab), a targeted therapy (cobimetinib), and a chemotherapy (eribulin) can shrink tumors in people with inflammatory breast cancer that has returned or spread. About 37 participants will receive either the trip…

This study tests whether adding the immunotherapy drug pembrolizumab to standard hormone therapy can help prevent recurrence in people with a rare, aggressive type of breast cancer called inflammatory breast cancer. Participants had hormone receptor-positive cancer that did not f…

This phase 2 trial is testing whether adding local treatments like surgery or high-dose radiation to standard chemotherapy or hormone therapy can help breast cancer patients whose disease has spread to 1–3 bones. The goal is to see if this combination keeps the cancer from progre…

This study tests whether adding a radioactive drug (radium-223) to standard chemotherapy (paclitaxel) helps people with advanced breast cancer that has spread to the bones. The radioactive drug targets bone tumors directly, while chemo works throughout the body. About 70 particip…

This early-phase trial tests whether a DNA vaccine made from a rat HER2 gene can safely stimulate the immune system in people with advanced or high-risk HER2-positive breast cancer. Thirteen participants receive multiple injections of the vaccine at different doses. The main goal…

This phase 3 trial is testing whether the drug trastuzumab deruxtecan (T-DXd), alone or with other chemotherapy drugs, works better than standard treatment before surgery in people with high-risk HER2-positive early breast cancer. About 927 participants will receive one of three …

This phase 2 trial tests whether continuing the drug palbociclib (Ibrance) while switching to a different hormone therapy, fulvestrant (Faslodex), can help control metastatic breast cancer in people whose disease has worsened on palbociclib plus an aromatase inhibitor. The study …

This study follows 400 women for 10 years to see how safe and effective Mentor MemoryGel Ultra High Profile breast implants are for breast reconstruction after mastectomy or for revision surgery. Researchers track problems like repeat surgeries, infection, and capsular contractur…

This study tests whether using highly focused radiation (SBRT) on a limited number of growing cancer spots can help control the disease in patients with metastatic breast or genito-urinary cancers. Instead of switching to a new drug when some tumors start growing, doctors will ta…

This phase 2 trial is testing the drug taletrectinib in people with a rare, advanced form of breast cancer called invasive lobular carcinoma that has a specific gene change (CDH1 mutation). The study aims to see if the drug can shrink tumors or slow the cancer's growth. The trial…

This early-stage trial is testing whether amivantamab, a drug that targets specific proteins on cancer cells, can be given as a shot under the skin instead of through an IV. About 158 adults with advanced solid tumors (like lung or head and neck cancers) will receive different do…

This phase 3 trial tests whether giving fulvestrant alone or with anastrozole before surgery works better than anastrozole alone for postmenopausal women with estrogen receptor-positive breast cancer. Over 1,400 participants will receive one of these hormone therapies for several…

This early-stage trial is testing a new drug called IDE161, alone or with the immunotherapy pembrolizumab, in adults with advanced solid tumors (like breast, ovarian, prostate, or lung cancer). The main goals are to check safety, find the right dose, and get a first look at wheth…

This study tests whether giving a single dose of radiation directly to the tumor site during breast-conserving surgery (lumpectomy) and before reconstruction is safe and effective for women with early-stage breast cancer. About 108 participants with stage I-II breast cancer will …

This early-phase study tests a new drug called M5A-IL2 immunocytokine together with precise radiation (SBRT) in people with advanced colorectal or breast cancer that has spread. The drug helps the immune system recognize and attack cancer cells. The goal is to find the safest dos…

This early-phase trial is testing whether adding a drug called copanlisib to the standard two-drug therapy (fulvestrant and abemaciclib) can better control hormone receptor-positive, HER2-negative metastatic breast cancer that has stopped responding to hormone therapy. The study …

This early-phase study tests a new drug called JANX008 in about 130 adults with advanced solid tumors, including lung, kidney, head and neck, colorectal, pancreatic, and breast cancers. The main goal is to check safety and find the right dose. Participants must have tried all sta…

This study tests whether platinum-based chemotherapy (cisplatin or carboplatin) works better than capecitabine in people with a certain type of triple-negative breast cancer that remains after initial chemotherapy and surgery. About 415 participants with stage II-III breast cance…

This phase III trial tests whether personalized therapy can improve survival for people with high-risk BRCA1-like breast cancer. Participants receive either standard chemotherapy or a more intense regimen with stem cell rescue. The study aims to find a better way to treat this ag…

This study tests the drug niraparib in 20 people whose cancer has spread to the brain or spinal cord. The goal is to see if the drug can shrink or control these tumors. Participants must have mild or no symptoms from their brain metastases and not need increasing steroids or seiz…

This study tests a new drug, DB-1303, against standard chemotherapy in about 540 people with a specific type of advanced breast cancer (HER2-low, hormone receptor-positive) that has stopped responding to hormone therapy. The main goal is to see if DB-1303 can delay cancer growth …

This early-phase study tests a new oral drug, ATV-1601, in people with advanced solid tumors or certain breast cancers that have a specific AKT1 E17K mutation. The main goals are to check safety, find the right dose, and see how the drug moves through the body. About 134 adults w…

This study tests four different tools—coaching, education, text messages, and health coaching—to help cancer survivors improve their diet, physical activity, and weight. About 350 adults who have completed treatment for several cancer types will use these tools for up to 48 weeks…

This study tests two drugs, olaparib and pembrolizumab, given before standard surgery for people with triple-negative or hormone receptor-positive HER2-negative breast cancer who have specific gene mutations. The goal is to see if the combination can shrink tumors enough to impro…

This phase 3 trial tests whether adding entinostat to the hormone therapy exemestane helps control advanced hormone receptor-positive breast cancer better than exemestane alone. About 600 patients with locally advanced or metastatic breast cancer are participating. The study meas…

This large phase III trial tests whether adding bevacizumab (a drug that blocks blood flow to tumors) to standard chemotherapy helps prevent breast cancer from coming back after surgery. About 5,000 patients with lymph node-positive or high-risk lymph node-negative breast cancer …

This study looks at whether using ultrasound before surgery can help identify women with early-stage HR+/HER2- breast cancer who have only a few affected lymph nodes. If so, they may be able to have a less invasive sentinel lymph node biopsy instead of a more extensive axillary l…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to standard chemotherapy (carboplatin and paclitaxel) before surgery helps shrink tumors in people with stage II-III triple negative breast cancer. About 67 participants will receive either chemo alone or…

This study tests the drug letrozole in postmenopausal women with early-stage ER+ breast cancer. Participants take letrozole for 4 to 24 weeks before surgery to see how the tumor changes and to check if they take the medication as prescribed. The goal is to improve treatment for t…

This early-stage trial is testing a new drug called tuvusertib, given together with either lartesertib or avelumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see how the body pr…

This early-stage trial tests a new drug called runimotamab, alone or with trastuzumab, in 123 people with advanced HER2-positive cancers. The main goal is to check safety and how the drug moves through the body. It is for patients whose cancer has spread or cannot be removed by s…

This early-phase trial tests a new drug called HRS8807, alone or with another drug SHR6390, in 46 people with ER-positive, HER2-negative breast cancer that has spread or cannot be removed. The main goal is to find safe doses and check for side effects. Participants have already t…

This study tests whether combining two drugs—cediranib (which cuts off a tumor's blood supply) and olaparib (which blocks cancer cell repair)—works better than olaparib alone for people with certain ovarian, fallopian tube, peritoneal, or triple-negative breast cancers that have …

This early-phase trial tests the safety of combining two cancer drugs, nivolumab and cabozantinib, in people with HIV who have advanced solid tumors. Only 8 participants were enrolled. The goal is to see if the combination is safe and can shrink or stabilize tumors.

This phase 2 study tests the drug entrectinib in over 500 people with advanced solid tumors that have specific gene changes (NTRK, ROS1, or ALK fusions). The goal is to see if the drug can shrink tumors and control the disease. Participants have various cancer types, including lu…

This early-stage trial tests a new drug, ALTA2618, in about 110 adults whose advanced solid tumors (like breast or endometrial cancer) have a specific genetic change called AKT1 E17K. The main goals are to check the drug's safety and find the right dose. Participants must have tr…

This study tests whether radiation therapy followed by injecting two targeted antibodies (trastuzumab and pertuzumab) directly into the spinal fluid is safe and improves survival for people with HER2+ breast cancer that has spread to the lining of the brain and spine. About 33 pa…

This study tests whether giving radiation over just 5 days in a row, instead of the usual longer schedule, is safe and works well for breast cancer patients who have had a mastectomy and breast reconstruction. The goal is to prevent cancer from coming back in the chest or nearby …

This early-stage trial tests an experimental oral drug called ZN-A-1041, alone or with other cancer drugs, in people with HER2-positive advanced solid tumors (including breast cancer that has spread to the brain). The study aims to find safe doses and check how the drug works in …

This study tests whether closely monitoring arm swelling after breast cancer surgery and treating it early with a compression sleeve can prevent long-term lymphedema. 250 women who had many lymph nodes removed will be randomly assigned to either the monitoring program or usual ca…

This phase 2 trial tests whether adding alpelisib to continued fulvestrant can help people with advanced, hormone-receptor-positive, HER2-negative breast cancer that has a PIK3CA mutation. Participants have already seen their cancer progress while on fulvestrant. The study aims t…

This phase II trial tests whether adding an immunotherapy drug (atezolizumab) to a targeted therapy (olaparib) works better than olaparib alone for advanced non-HER2-positive breast cancer that has a BRCA mutation. About 81 patients with locally advanced or metastatic disease are…

This phase 2 trial tests a treatment called LN-145, made from a patient's own immune cells taken from their tumor. These cells are grown in a lab and then given back to the patient to attack the cancer. The study includes people with ovarian cancer, triple-negative breast cancer,…

This study tests whether the drug ixabepilone can help people with HER2-negative breast cancer who still have significant cancer after standard chemotherapy. About 116 participants will either receive ixabepilone or standard care. The goal is to see if ixabepilone improves outcom…

This early-phase trial tests a combination of two drugs—veliparib and carboplatin—in people with HER2-negative breast cancer that has spread. The goal is to find the best dose and see if the combo is safe. Veliparib may help carboplatin work better by stopping cancer cells from r…

This phase 2 trial is testing a higher dose (500 mg) of the hormone therapy fulvestrant (Faslodex) as a first treatment for postmenopausal women with hormone receptor positive metastatic breast cancer. The study aims to see if this higher dose improves clinical benefit rates comp…

This early-stage trial tests a new drug called LY4101174 in people with advanced solid tumors, including bladder, breast, and lung cancers. The drug is an antibody-drug conjugate designed to target and kill cancer cells. The study will check if the drug is safe, tolerable, and ef…

This study tests a new drug called trastuzumab deruxtecan (T-DXd), given alone or with another drug (pertuzumab), against the current standard treatment for HER2-positive breast cancer that has spread. About 1,157 people with this type of cancer will take part. The goal is to see…

This phase 2 trial is testing whether adding the immunotherapy drug atezolizumab to a standard combination of chemotherapy (paclitaxel) and two targeted drugs (trastuzumab and pertuzumab) is safe and effective for people with advanced HER2-positive breast cancer that has spread. …

This study looks at whether adding surgery or radiation to a standard drug combination (palbociclib plus letrozole) can help people with newly diagnosed stage IV ER+/HER2- breast cancer live longer. About 200 women with cancer that has spread beyond the breast will receive the dr…

This study looks at whether adding a CDK4/6 inhibitor (a targeted drug) to hormone therapy earlier or later works better for women with advanced hormone-receptor-positive breast cancer. About 1,050 women will receive either the drug combo first followed by another hormone therapy…

This Phase 3 trial is testing whether a new drug called giredestrant, combined with palbociclib, works better than the standard letrozole plus palbociclib for people with a common type of advanced breast cancer (ER-positive, HER2-negative). About 992 participants will receive eit…

This study tests whether a shorter, more focused radiation treatment (accelerated partial breast irradiation) after breast-conserving surgery can effectively control cancer in the breast and nearby lymph nodes for people with early-stage breast cancer. About 537 participants with…

This study is testing a program called WeCan-Rural for breast cancer survivors living in rural, underserved areas. The program includes 12 weekly video sessions to help manage symptoms like pain and fatigue, and build healthy habits around eating, exercise, and weight. The goal i…

This study looks at whether surgically removing the primary breast tumor (along with standard chemotherapy) helps women with oligometastatic breast cancer—cancer that has spread to only a few spots in the body—live longer. About 110 women in Pakistan will either receive surgery p…

This study tests a new drug (PF-07220060) plus letrozole against standard treatments for people with HR-positive, HER2-negative advanced or metastatic breast cancer who haven't had prior therapy for advanced disease. About 1,035 adults will be randomly assigned to either the new …

This phase 2 trial tests whether giving sacituzumab govitecan and pembrolizumab before surgery can help control early-stage triple-negative breast cancer that didn't respond to initial chemotherapy and immunotherapy. The study enrolls 27 adults with specific tumor types. The main…

This study tests a drug called T-DM1 in older adults (age 60+) with HER2-positive breast cancer after surgery. The goal is to see if it can prevent the cancer from coming back. About 111 participants received the drug, and researchers are tracking how long they stay cancer-free.

This study tests whether a web application can help breast cancer patients take their hormone therapy as prescribed. About 438 patients starting hormone therapy will either use the app or receive standard care. The goal is to see if the app improves medication adherence and quali…

This study tests two drugs, niraparib and dostarlimab, given before surgery to people with BRCA- or PALB2-mutated breast cancer. The goal is to see if this combination boosts the immune system's attack on the tumor and leads to a complete response (no cancer left at surgery). Abo…

This study tests a new drug called BL-M07D1, alone or combined with other medicines, as a first treatment for people with advanced HER2-positive breast cancer that cannot be removed by surgery. The goal is to see if these treatments shrink tumors and how safe they are. About 83 a…

This phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…

This phase 2 trial is testing whether a combination of ribociclib (Kisqali) and letrozole can safely replace chemotherapy for people with high-risk ER+/HER2- breast cancer. About 1100 participants will first receive the drug combo before surgery. If their tumor shows a low risk o…

This study tests whether adding the immunotherapy drug toripalimab to standard chemotherapy before surgery can completely eliminate tumors in people with localized triple-negative breast cancer. About 51 women with early-stage, untreated disease will receive the combination, then…

This study tests whether adding a non-invasive heat therapy called modulated electro-hyperthermia (mEHT) to standard chemotherapy can shrink tumors more effectively in women with HER2-negative breast cancer. About 71 participants with stage II-III disease will receive chemo with …

This early-stage trial tests a new drug called YL202 in about 80 people with advanced lung or breast cancer that has not responded to standard treatments. The drug is given by IV every three weeks. The main goal is to check safety and find the right dose, not yet to prove it work…

This early-stage trial tests a drug called berzosertib combined with radiation therapy for people with certain types of breast cancer that no longer respond to chemotherapy. The goal is to find the safest dose and see if the combination can shrink or stabilize tumors better than …

This early-stage trial is testing a new drug called GDC-9545 (giredestrant), alone or combined with other medications, in people with advanced ER-positive breast cancer that has spread. The main goals are to check safety, find the best dose, and see if it shrinks tumors. About 18…

This phase 3 trial tests a new drug called Dato-DXd against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. About 644 participants will be randomly assigned to receive either Dato-DXd or one of several chemotherapy dr…

This study tests a newer targeted therapy, trastuzumab deruxtecan (T-DXd), against an older one, trastuzumab emtansine (T-DM1), in about 1,600 people with high-risk HER2-positive breast cancer who still have cancer after initial treatment. The goal is to see if T-DXd can better p…

This early-stage trial tests a new oral drug called ceralasertib, given alone or with other cancer treatments like chemotherapy or targeted drugs, in 354 adults with advanced solid tumors that no longer respond to standard care. The main goal is to check safety and find the best …

This study tests a combination of targeted drugs (ribociclib, tucatinib, trastuzumab, with or without fulvestrant) for HER2-positive breast cancer. In the first part, it looks at safety in patients whose cancer has spread. In the second part, it compares these drugs to standard c…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This study looks at whether a targeted therapy called palbociclib, taken for 2 years alongside standard hormone therapy, can help prevent breast cancer from coming back in older patients with high-risk ER+/HER2- early breast cancer. The goal is to offer an effective alternative t…

This early-phase trial tests a dendritic cell vaccine given directly into the spinal fluid for people with breast cancer that has spread to the lining of the brain (leptomeningeal disease). The vaccine is designed to train the immune system to attack cancer cells. The main goal i…

This study tests whether extra care from a team of heart doctors, dietitians, exercise therapists, pharmacists, and physiotherapists can reduce side effects in breast cancer patients receiving chemotherapy. About 80 participants will be randomly assigned to either the team interv…

This study compares active monitoring (regular checkups without immediate treatment) to surgery for people with low-risk ductal carcinoma in situ (DCIS), a very early form of breast cancer. About 1,000 participants are being followed for two years to see if monitoring is as good …

This study tests the drug trastuzumab deruxtecan in about 500 people with advanced HER2-positive breast cancer, some of whom also have brain metastases. The goal is to see how well the drug shrinks tumors and how long it keeps the cancer from growing. Participants receive the dru…

This phase II trial at Mayo Clinic tests whether estradiol, a form of estrogen, can help patients with a specific subtype of triple negative breast cancer that has a receptor called ER beta. The study enrolls 8 women with advanced or metastatic disease. Researchers will measure h…

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This study tests if a combination of ribociclib (a targeted pill) and hormone therapy works better than standard chemotherapy for women with a common type of early breast cancer (HR+/HER2-). About 1,684 women with intermediate-risk disease are taking part. The goal is to see whic…

This study looks at whether women with early breast cancer (tumors smaller than 5 cm) and no signs of cancer in the lymph nodes can safely avoid axillary surgery. About 800 women will be randomly assigned to either have a sentinel lymph node biopsy or no surgery at all. The goal …

This study tests whether adding the drug ipatasertib to standard chemotherapy and immunotherapy (atezolizumab) can improve outcomes for women with high-risk triple-negative breast cancer before surgery. About 146 women with newly diagnosed, non-metastatic tumors that are at least…

This phase 2 study tests a new drug called SKB264, alone or with another drug KL-A167, in 175 people with advanced HER2-negative breast cancer that hasn't been treated before. The goal is to see if the combination is safe and can shrink tumors. Participants are split into groups …

This study tests a drug called trastuzumab-deruxtecan (T-DXd) in 28 people with HER2-low breast cancer that has spread to the brain. The goal is to see if the drug can shrink brain tumors. Participants receive the drug intravenously, and doctors monitor tumor response using brain…

This early-stage trial tests a personalized treatment for people with metastatic solid cancers that have KRAS mutations. Doctors take a patient's own white blood cells, genetically modify them to recognize and attack KRAS-mutated cancer cells, and return them to the patient along…

This study tests giving radiation therapy before surgery to women aged 50+ with early-stage, hormone-positive breast cancer. The goal is to find the safest radiation dose and see how the tumor responds. Only 15 participants are enrolled, making this a very early-stage trial.

This early-stage study tests a new drug called A166 in 120 adults with advanced HER2-positive solid tumors that have spread or cannot be removed by surgery. The main goal is to check safety and find the right dose, while also seeing if the drug shrinks tumors. Participants must h…

This phase 3 trial compares a standard 3-week radiation course to an experimental 2-week course for women with early-stage breast cancer. About 400 participants who had lumpectomy will receive whole breast radiation plus an extra boost to the tumor site. The study checks if the s…

This Phase 2 trial tests the drug elacestrant in 61 people with estrogen receptor-positive, HER2-negative metastatic breast cancer who have not previously used CDK4/6 inhibitors. Participants take a daily pill for about 6 months. The study aims to see if the drug can delay cancer…

This study looks at whether women with aggressive breast cancers (triple-negative or HER2-positive) who have a complete response to chemotherapy can safely avoid sentinel lymph node biopsy. The trial will enroll 350 patients across Europe, all of whom will have breast-conserving …

This phase 3 trial compares a new drug called A166 to the standard drug T-DM1 in about 365 people with HER2-positive breast cancer that cannot be removed by surgery or has spread to other parts of the body. Participants must have already been treated with trastuzumab and a taxane…

This Phase 3 trial tests a new chemotherapy drug called SKB264 against standard chemotherapies in 254 people with advanced triple-negative breast cancer that has worsened after at least two prior treatments. The main goal is to see if SKB264 can delay cancer growth longer than th…

This study tests a modified radiation schedule for women aged 50 and older with early-stage, low-risk breast cancer. Instead of the standard every-other-day treatment over 10 days, participants receive five daily radiation sessions with a slightly lower dose each day. The goal is…

This early-phase trial is testing a gel form of the drug endoxifen, applied to the skin, in 32 women scheduled for breast surgery. The goal is to see if the gel is safe and how much of the drug gets into breast tissue and blood. If successful, it might offer a gentler way to trea…

This Phase 3 trial is testing an experimental drug called Dato-DXd against standard chemotherapy in 732 people with advanced HR-positive, HER2-negative breast cancer. Participants have already tried one or two prior chemotherapies. The study aims to see if Dato-DXd can slow cance…

This phase II trial tests a drug called sacituzumab govitecan in 44 patients with HER2-negative breast cancer that has spread to the brain. The drug is a targeted antibody that delivers chemotherapy directly to cancer cells. The goal is to see if it can shrink brain tumors or slo…

This study tests whether a single, focused radiation treatment works as well as five treatments for people with low-risk stage 0 or I breast cancer after a lumpectomy. About 134 participants will be randomly assigned to receive either one or five doses of radiation to the tumor a…

This study tests two oral medications, vepdegestrant and samuraciclib, taken daily at home by adults with advanced or metastatic ER+ breast cancer that no longer responds to standard treatments. The goal is to see if the combination is safe and can shrink or control the cancer. P…

This study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy before surgery can help the immune system fight triple-negative breast cancer more effectively. About 15 people with early-stage (stage II or III) triple-negative breast cancer will receive …

This pilot study tests two oral drugs, anastrozole and palbociclib, in postmenopausal women with a common type of metastatic breast cancer (HR+/HER2-). The drugs are given either as the first treatment or as maintenance after chemotherapy. The main goal is to see if the combinati…

This phase 3 trial compares giving hormone therapy (aromatase inhibitors) at the same time as chemotherapy versus after chemotherapy in 1000 postmenopausal women with early breast cancer. The goal is to see which timing better prevents the cancer from coming back over 15 years. P…

This phase 3 trial tests whether adding the drug carboplatin to standard chemotherapy (doxorubicin, cyclophosphamide, and paclitaxel) helps prevent triple-negative breast cancer from coming back. About 782 patients with high-risk or node-positive disease are participating. The st…

This study tests whether the drug olaparib can help prevent breast cancer from returning in people with inherited BRCA1 or BRCA2 mutations who have already completed surgery and chemotherapy. About 1,800 participants with high-risk, HER2-negative breast cancer will receive either…

This study tests a new drug called PF-07104091 in people with advanced small cell lung cancer, ovarian cancer, or certain breast cancers that have not responded to prior treatments. The goal is to find the safest dose and see if the drug shrinks tumors, either alone or with other…

This study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…

This was a phase II trial testing a combination of three drugs—zimberelimab, domvanalimab, and sacituzumab govitecan—as a first treatment for people with advanced triple-negative breast cancer that is PD-L1 positive. The study aimed to see how well the drugs shrank tumors and how…

This early-stage trial tests two drugs, alpelisib and sacituzumab govitecan, together in people with advanced HER2-negative breast cancer that has spread or come back. The main goal is to find the safest dose and check for side effects. About 18 adults are taking part in this stu…

This phase II trial is testing a type of radiation called proton beam therapy for women with early-stage breast cancer (stage 0 to II). The goal is to see if this targeted approach can kill cancer cells while causing less damage to normal tissue, leading to fewer side effects and…

This study compares two approaches for women with early-stage invasive breast cancer undergoing breast-conserving surgery: no axillary surgery versus sentinel lymph node biopsy. The goal is to see if avoiding axillary surgery leads to the same cancer outcomes while reducing compl…

This phase III trial tests whether a less extensive lymph node surgery (tailored axillary surgery) followed by radiotherapy works as well as the standard full lymph node removal in women with breast cancer that has spread to the lymph nodes. The study involves 1,500 participants …

This study tested different chemotherapy combinations and schedules for women with breast cancer that had spread to lymph nodes. The goal was to see if adding a drug called fluorouracil or giving chemo every 2 weeks (with a support drug to boost immune recovery) worked better tha…

This early-phase trial tests a new drug called AZD9833, alone or with other medicines, in women with a specific type of advanced breast cancer (ER-positive, HER2-negative). The main goals are to check safety and find the right dose. About 396 women will take part. This is not a c…

This phase 3 trial tests whether adding capivasertib to standard fulvestrant therapy can slow cancer growth in people with advanced HR+/HER2- breast cancer. About 818 participants whose cancer worsened after hormone therapy will receive either the combination or a placebo plus fu…

This phase 2 trial tests whether the number of immune cells in and around a triple-negative breast cancer tumor can help doctors personalize chemotherapy and immunotherapy. About 139 women with early-stage triple-negative breast cancer will receive standard chemotherapy drugs plu…

This study tested a combination of two immunotherapy drugs, nivolumab and ipilimumab, in 30 people with a rare, advanced form of HER2-negative breast cancer that has many genetic mutations (hypermutated). The goal was to see if this drug pair could shrink or control the cancer. P…

This study looks at a new material called SC Derm, used in breast reconstruction after mastectomy for breast cancer. It compares how well this material works and its safety against other similar products. About 120 women aged 20 to 69 who are having a mastectomy and immediate imp…

This phase 2 trial is testing whether a combination of targeted cancer drugs (trastuzumab, pertuzumab, and T-DM1) can effectively treat HER2-positive early breast cancer without traditional chemotherapy. About 393 patients will receive these drugs as a subcutaneous injection, wit…

This Phase III trial is testing whether women and men with early-stage, low-risk HER2-positive breast cancer can safely skip radiation after breast-conserving surgery if they continue HER2-targeted therapy. About 1,300 participants are randomly assigned to receive either standard…

This trial tests a nurse-led health program for women aged 45 to 64 in Hong Kong. The program uses a 5-step approach (ask, advice, assess, assist, arrange) to help women manage conditions like high blood pressure, anxiety, and menopause symptoms. Researchers will compare the prog…

This early-phase trial tests a new oral drug, SH3765, combined with the injectable hormone therapy fulvestrant in 30 women with advanced HR+/HER2- breast cancer that has worsened after prior treatment. The main goals are to check safety, find the best dose, and see if the combina…

This study tests whether a 3-month program of dance classes three times a week plus a personalized nutrition plan can improve health in 40 obese breast cancer survivors. Researchers will measure changes in weight, body fat, fitness, gut bacteria, and quality of life. Participants…

This study tested a combination of three drugs (atezolizumab, pertuzumab, and high-dose trastuzumab) in 19 people with HER2-positive breast cancer that had spread to the brain. The goal was to see if the treatment could shrink or control brain tumors. While the approach aims to m…

This phase 2 trial tests a two-step treatment for people with HER2-positive breast cancer that has spread or cannot be removed by surgery. First, patients receive a strong drug called trastuzumab deruxtecan (T-DXd) to shrink the cancer. Then, they switch to a maintenance therapy …

This phase 2 trial tests whether adding an immunotherapy drug called IRX 2 to standard pembrolizumab (Keytruda) and chemotherapy can improve outcomes for people with triple-negative breast cancer. The study involves 12 participants who receive the combination before surgery. The …

This study tested whether adding the immunotherapy drug pembrolizumab to standard chemotherapy is safe and works for people with metastatic triple negative breast cancer, a hard-to-treat form. 29 adults with advanced cancer that had spread or could not be removed by surgery took …

This phase 3 study tests whether adding the targeted drug abemaciclib to standard hormone therapy helps prevent breast cancer from returning in people with high-risk, early-stage, hormone receptor-positive, HER2-negative breast cancer that has spread to lymph nodes. Over 5,600 pa…

This study tests whether combining the immunotherapy drug durvalumab with other cancer treatments (with or without chemotherapy) can help control metastatic triple negative breast cancer in people who have not had prior treatment for advanced disease. About 243 women with advance…

This phase 3 trial tests whether switching to a new oral drug (AZD9833) plus a CDK4/6 inhibitor can delay cancer progression better than staying on standard aromatase inhibitor therapy in people with HR+/HER2- metastatic breast cancer who have an ESR1 mutation. About 315 particip…

This pilot study tests a remotely-delivered nutrition and cooking program called MIND for stage I-III breast cancer survivors. The program is delivered online through the Cook for Your Life platform and aims to improve diet quality. The study will enroll 49 participants to see if…

This phase 2 trial tests whether adding the immunotherapy drug atezolizumab to the chemotherapy pill capecitabine helps prevent cancer from coming back in people with triple-negative breast cancer who still had cancer after initial chemotherapy and surgery. About 284 participants…

This Phase 3 trial tests whether the drug sacituzumab govitecan (Trodelvy) can prevent breast cancer from returning in patients with HER2-negative breast cancer who still have cancer after initial chemotherapy. About 1,332 participants will receive either the new drug or standard…

This study tests a technique called axillary reverse mapping (ARM) to see if it can prevent lymphedema—painful arm swelling—after breast cancer surgery. About 534 people with stage I-III breast cancer will be followed for 3 years. The goal is to find out if mapping and preserving…

This early-stage study tests an oral drug called LY3410738 in people with advanced solid tumors (like bile duct cancer, cartilage cancer, or brain tumors) that have specific IDH1 or IDH2 mutations. The main goal is to find a safe dose and see if the drug can shrink tumors. About …

This phase II trial is testing a combination of four drugs—trilaciclib, pembrolizumab, gemcitabine, and carboplatin—in people with advanced triple-negative breast cancer that cannot be removed by surgery or has spread. The study aims to see how well the treatment works and how sa…

This early-stage trial tests a treatment called HER2-CAR T cells for people with HER2-positive cancers that have spread to the brain or its lining. The cells are given directly into the brain's fluid spaces to try to kill tumor cells. The main goals are to find the safest dose an…

This Phase 3 trial tests whether adding tucatinib (a targeted pill) to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2+ breast cancer. About 654 participants with inoperable or metastatic disease will receive either tucatinib or …

This phase 3 study compares a new drug, BL-B01D1, to standard chemotherapy in 418 people with advanced triple-negative breast cancer that has stopped responding to taxane chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth and extend survival. Participants must be…

This phase 2 trial tests whether adding the immunotherapy drug durvalumab to two standard targeted drugs (trastuzumab and pertuzumab) can shrink tumors more effectively in people with HER2-enriched breast cancer. The study involves 51 participants and measures how many have no or…

This study is testing a shorter, more intense radiation schedule (hypofractionation) for women with breast cancer who have had surgery. The goal is to see if this approach is safe and effective at preventing cancer from coming back while reducing side effects like arm swelling. F…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…

This study tests whether giving the immunotherapy drug pembrolizumab (Keytruda) along with a small dose of radiation to the tumor before standard treatment (surgery, chemotherapy, or radiation) is safe and helps the immune system fight breast cancer. About 66 people with operable…

This early-phase study tests a new oral drug called MOMA-313, alone or with another drug (olaparib), in people with advanced solid tumors that have certain DNA repair flaws. The main goals are to check safety and find the right dose. About 220 adults with cancers like prostate, p…

This phase 2 trial tests whether combining immunotherapy (avelumab) with other drugs can shrink tumors in people with advanced triple-negative breast cancer that has spread or come back. About 145 participants will receive one of several drug combinations, including avelumab plus…

This study tests whether giving two targeted drugs, T-DM1 and pertuzumab, before surgery can completely eliminate early-stage HER2-positive breast cancer. About 164 participants with stage II or III disease will receive the drugs for 18 weeks, then undergo surgery. The main goal …

This study tests a new drug called BL-B01D1 against standard chemotherapy in about 383 people with advanced HR+HER2- breast cancer that has not responded to at least one prior chemotherapy. The goal is to see if BL-B01D1 can slow cancer growth or improve survival. Participants ar…

This phase 1 trial is testing a new imaging tracer called 68Ga-FAPI-46 to see where it collects in normal and cancerous tissues. About 30 people with various solid tumors or blood cancers will receive the tracer and then undergo a PET/CT scan. The goal is to understand how the tr…

This phase 2 trial tests whether a PET scan using a radioactive form of estrogen (FES) can predict how well endocrine therapy works in 99 women with newly diagnosed metastatic breast cancer. The scan lights up cancer cells that have estrogen receptors, helping doctors see if the …

This study tests a new microwave scanner that measures the electrical properties of breast tissue. Researchers will compare these scans to standard mammograms and ultrasounds in 100 women who need follow-up breast imaging. The goal is to see if microwave imaging can help detect b…

This early-phase trial tests a radioactive imaging agent called Technetium-99m HYNIC-FAPI in 15 people with metastatic lung, pancreas, breast, or colorectal cancer. The goal is to see how well it highlights tumors on SPECT/CT scans. Researchers will measure where the agent goes i…

This phase 2 trial is testing a new imaging agent called [99mTc]Tc-ZHER2:4107 to see how well it can detect different levels of HER2 protein in breast cancer tumors. Fifty participants will receive one injection followed by a SPECT/CT scan. The goal is to improve diagnosis and he…

This study tests a radioactive imaging agent called [99mTc]Tc-DB8 to see if it can help doctors see breast cancer tumors and tell whether they are estrogen receptor positive or negative. Forty women with primary breast cancer will get one injection of the agent, followed by a SPE…

This study is testing a new mammography device to see if it can safely produce clear images for breast cancer screening and diagnosis. About 7,500 women aged 35 and older who need a mammogram or breast biopsy will get an extra scan with the new device. The goal is to check image …

This phase 2 trial tests whether a special PET/CT scan using a radioactive tracer (FDG) can predict how well HER2-positive breast cancer responds to standard chemotherapy before surgery. About 235 patients with stage II-III HER2+ breast cancer will get the scan early in treatment…

This study tests whether a special type of ultrasound, using a contrast dye called Definity, can measure pressure inside breast tumors to predict how well chemotherapy is working. About 200 women with locally advanced breast cancer will get three of these ultrasounds before and d…

This study tests whether a newer PET scan tracer (68Ga-FAPI-46) is better than the standard one (18F-FDG) at finding how far lobular breast cancer has spread. About 40 adults with untreated lobular breast cancer will get both scans, and doctors will compare how many tumor spots e…

This phase 2 trial tests whether a new radioactive tracer called [18F]FluorThanatrace can improve PET/CT scans in 36 people with breast cancer. The tracer is designed to highlight an enzyme linked to cancer growth. Participants will receive the tracer before their standard surger…

This study tests a new MRI technique called virtual MR elastography (vMRE) that uses standard scans to measure breast tissue stiffness, which can help tell benign from malignant lesions. Researchers will compare vMRE to the traditional MRE method in 238 women with suspicious brea…

This study is testing whether a special MRI that does not require a contrast dye injection can accurately detect breast cancer or other breast diseases. Over 1,000 women at risk or with suspected breast issues will receive the new MRI alongside standard care. The goal is to see i…

This study is testing whether a simple breath test can tell if a woman has breast cancer. Researchers are collecting breath samples from 1000 women — half with breast cancer and half without — and analyzing them with a mass spectrometer. The goal is to see if the chemical signatu…

This phase 1 trial tests whether a new radioactive imaging agent, 89Zr-ss-pertuzumab, is safe for detecting HER2-positive breast cancer in 60 participants. The agent is designed to bind to HER2 proteins on cancer cells and show up on PET/CT scans. The main goal is to check for si…

This study tests whether checking sentinel lymph nodes during breast cancer surgery (using a rapid freezing method) helps surgeons decide right away if more lymph nodes need to be removed, compared to the usual method of waiting for final results after surgery. About 142 women wi…

This study is testing a short (under 5 minutes) MRI technique called DWI that does not require an injection of contrast dye. The goal is to see if it can find breast cancers that mammograms miss in women with dense breasts. About 269 women with dense breasts will participate. If …

This study compares breast ultrasound with two types of breast MRI (abbreviated and full protocol) for detecting new breast cancers in women who have dense breasts and a personal history of breast cancer. About 1,756 women will be randomly assigned to one of the screening methods…

This study is testing an artificial intelligence (AI) tool that analyzes digitized images of tumor tissue from 2,200 women with ER-positive, HER2-negative early breast cancer. The AI aims to predict the risk of cancer spreading to distant parts of the body. Researchers will compa…

This phase 3 trial is comparing two types of mammograms—standard 2D digital mammography and newer 3D tomosynthesis—to see which is better at finding advanced breast cancers early. Over 108,000 women are taking part, and researchers will track cancer diagnoses over 4.5 years. The …

This study tests a natural substance called GM1 to see if it can prevent nerve damage (pain, numbness, tingling) caused by the chemotherapy drug paclitaxel in people with metastatic breast cancer. About 98 participants will receive either GM1 or a placebo alongside their chemo. T…

This study tests a web-based nurse navigator program designed to encourage breast cancer screening (mammograms, breast self-exams, and clinical exams) in women at high risk for breast cancer. 104 women aged 30-70 who haven't had a mammogram in the last year are participating. The…

This study tests whether a patient navigator—a guide who helps women understand their options—can improve how high-risk women manage their breast cancer risk. About 75 women with a family history of breast cancer but no personal diagnosis will receive support to make informed cho…

This phase 3 trial tests whether taking metformin for 12 months can reduce abnormal cells in the breast tissue of women at high risk for breast cancer. Participants have conditions like atypical hyperplasia or a strong family history. Researchers compare metformin to a placebo to…

This phase 2 trial is testing whether gradually increasing the dose of abemaciclib (a targeted cancer drug) can reduce side effects like diarrhea and help patients stick with treatment. It involves 90 people with early-stage, hormone receptor-positive, HER2-negative breast cancer…

This study looks at whether a mobile health program that combines physical activity tracking with mindfulness lessons can help breast cancer survivors become more active and feel better. About 304 women who finished cancer treatment within the past 5 years will take part in a 24-…

This study tests whether training the muscles you use to breathe can improve how long obese breast cancer survivors can exercise. Researchers will compare breathing exercises plus aerobic exercise to aerobic exercise alone in 78 women who finished treatment. The goal is to see if…

This study tests whether a headband with special semiconductors can help with memory and thinking problems (often called 'chemo brain') in people who have had breast or gynecologic cancer. About 50 participants will wear either the active headband or a placebo version for 18 hour…

This study tests fezolinetant, a non-hormonal drug, for treating hot flashes in women with hormone-positive breast cancer who are on hormone therapy. About 984 women will take either fezolinetant or a placebo daily for a year. The goal is to see if fezolinetant reduces the number…

This study looks at whether writing about their experiences can improve the health of Asian American breast cancer survivors. About 192 people who finished cancer treatment in the last 5 years will take part. They will write and report how they feel, and researchers will track an…

This study tests if whole-body cryotherapy (brief exposure to extreme cold) can reduce joint pain caused by aromatase inhibitors, a common hormone therapy for breast cancer. About 70 women will be randomly assigned to either a real or placebo cryotherapy session. Researchers will…

This study tests a drug called elinzanetant to see if it can reduce hot flashes in women with hormone-receptor positive breast cancer who are on hormone-blocking therapy. About 474 women will take either the drug or a placebo for 12 weeks, then all will receive the drug for up to…

This study compares two types of nerve blocks (retrolaminar block vs. serratus anterior plane block) to see which provides better pain relief after radical mastectomy. About 90 women aged 25-65 undergoing breast cancer surgery will receive one of the blocks before general anesthe…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests an exercise program designed for Hispanic women who have had breast cancer. The goal is to find the best ways to help them become more physically active. Researchers will measure changes in exercise habits and look at certain health markers in the blood. The stud…

This study compares a new counseling approach called Acceptance and Commitment Therapy (ACT) with standard counseling to help people with head and neck, lung, breast, gastrointestinal, or genitourinary cancer stop smoking. About 51 adults who smoke at least one cigarette per day …

This study tests two ways to cool the scalp during chemotherapy to prevent hair loss in women with localized breast cancer. One uses a standard cold cap with a compression bandage, the other a cooling mask. Researchers will compare how well each prevents hair loss, and also look …

This study tests a mobile lifestyle program for women with breast cancer who have unhealthy habits. The program offers coaching on diet, exercise, stress management, mindfulness, and sleep. Researchers want to see if it's practical and helps improve quality of life. About 30 wome…

This study tests whether a 6-week online yoga program can improve quality of life, reduce joint pain, and lessen night sweats and hot flashes in women with breast cancer who are taking endocrine therapy. About 64 women will take part, with half doing yoga four days a week and the…

This study tests a mindfulness-based program (Nite2Day) for women with breast cancer who have trouble sleeping. Participants learn strategies to cope with insomnia, fatigue, stress, and pain during six remote sessions with a therapist. The goal is to see if the program is practic…

This study tests whether sexual counseling delivered via WhatsApp can help breast cancer survivors who have sexual problems after treatment. About 86 women who have had mastectomy and finished chemo/radiotherapy will receive counseling using the EX-PLISSIT model. The goal is to s…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study looks at whether providing food assistance—like vouchers, grocery delivery, or a hospital food pantry—helps cancer patients finish their treatment. About 600 patients with breast cancer who struggle to afford food will be randomly assigned to one of three programs. Res…

This study tests whether eating a low-calorie diet before chemotherapy can reduce side effects like fatigue, nausea, and mouth sores, and also improve how well the treatment works. About 130 people with breast or prostate cancer will be randomly assigned to either follow the diet…

This study tested if a scalp cooling cap set to a colder temperature than usual can safely prevent hair loss in breast cancer patients receiving chemotherapy. 34 adults with stage I-III breast cancer took part. The goal was to see if the lower temperature is safe and tolerable.

This study tests whether a cream made with caffeine can help prevent skin hardening and other complications in breast cancer patients who need radiation after mastectomy with tissue expander reconstruction. About 60 participants will use either the caffeine cream or a placebo cre…

This study is testing several new, minimally invasive surgical techniques for breast augmentation and reconstruction. The goal is to preserve natural breast tissue, reduce recovery time, and improve how the breasts look and feel. About 60 women aged 18 and older with cup sizes AA…

This study looks at whether starting a stress-reduction program before chemotherapy can improve mood, stress, and physical symptoms in women newly diagnosed with breast cancer. About 62 women with stage I-III breast cancer will take part. Researchers will track changes in symptom…

This study tests whether a 10-week video-based stress management program (VSMART) is practical and helpful for 25 breast cancer survivors in Alabama. Participants join group discussions from home. The goal is to see if the program improves wellbeing and to gather feedback from su…

This pilot study tests whether a home-based virtual program of cardio and yoga (IM@Home) can help breast cancer patients undergoing radiation feel less fatigued and more active. Forty participants will wear a FitBit and attend online classes. The goal is to see if the program is …

This study tests whether coaching people with breast cancer on diaphragmatic breathing helps them take larger, more consistent breaths during radiation therapy. Better breath holds can protect nearby organs like the heart and lungs. The study involves 40 adults and uses lung func…

This phase 2 study tests whether acupuncture can improve memory, focus, and thinking problems (often called 'chemo brain') in people who have had breast, colorectal, prostate, or gynecological cancer. About 48 participants will receive either real acupuncture or sham (fake) acupu…

This study looks at whether writing about your thoughts and feelings about breast cancer can improve quality of life. About 272 people recently diagnosed with breast cancer will be asked to write for 20 minutes once a week for four weeks. They will fill out questionnaires to meas…

This phase 2 trial tests whether injecting platelet-rich plasma (PRP) into the vulva and vagina can improve symptoms of genitourinary syndrome of menopause (GSM) in breast cancer survivors. GSM causes dryness, burning, and pain, often worsened by cancer treatments. The study enro…

This study looks at whether a 12-week dance program can reduce pain, fatigue, and improve quality of life in women being treated for breast cancer. Twenty-eight women will either take dance classes twice a week or continue their normal routine. Researchers will measure changes in…

This study is testing whether a 9-month, individually tailored exercise program can reduce physical fatigue and improve quality of life in 357 people with stage IV breast cancer. Participants work with a trained instructor to follow a personalized exercise plan. The main goal is …

This study looks at whether women aged 65 and older with early-stage, estrogen-positive breast cancer can safely have a lumpectomy without also removing and testing nearby lymph nodes (sentinel node biopsy). The goal is to see if skipping this extra step leads to cancer coming ba…

This study tests whether a 20-week program of exercise alone or exercise combined with cognitive training can improve thinking and memory in breast cancer survivors. 108 women who have finished primary treatment will be assigned to one of three groups: dual-task training, exercis…

This study tests whether a type of pain education that teaches the brain's role in pain, combined with motivational interviewing, can reduce chronic pain in breast cancer survivors. 156 women who have finished primary treatment and still have pain will be randomly assigned to thi…

This study tests a geriatric care survivorship program for adults aged 65 and older who have finished curative treatment for early-stage breast cancer. The program includes a full health assessment, education, activity tracking, and supportive care. Researchers hope this approach…

This study compares a single dose of radiation given during breast cancer surgery (IORT) to standard whole breast radiation given over weeks. The goal is to see if IORT causes less fatigue in women with low-risk early breast cancer. About 100 women aged 50 and older with small, h…

This study compares two relaxation programs (including stretching and relaxation techniques) to see if they improve physical and emotional well-being in women with breast cancer undergoing radiation therapy. About 700 women with early-stage breast cancer will participate, with so…

This study aims to develop and test a shortened version of Mindfulness-Based Cognitive Therapy (MBCT) to improve mood in older African American/Black women who have had breast cancer and now have mild to moderate depression. About 23 participants will attend group sessions and re…

This study tests whether a therapy program that combines in-person sessions with a smartphone app can help cancer patients feel more flexible in dealing with difficult thoughts and emotions. About 120 adults with breast, lung, or colorectal cancer will be randomly assigned to one…

This study tests four different vaginal treatments (estrogen, DHEA, estrogen with probiotics, and a moisturizer) in 160 breast cancer patients who have vaginal atrophy due to hormone therapy. The goal is to see which treatment best relieves symptoms like dryness and pain, and imp…

This pilot study tests whether a non-invasive brain stimulation technique called transcranial direct current stimulation (tDCS), combined with cognitive training, is feasible and tolerable for breast cancer survivors who have memory or thinking problems after chemotherapy. The st…

This study tests an online self-help program called Together After Cancer for Latina breast cancer survivors and their intimate partners. The program includes brief coach calls and aims to improve the survivor's quality of life and the couple's relationship satisfaction. About 48…

This study tests whether a painkiller called suzetrigine can reduce pain after breast surgery (not mastectomy). About 120 adults will take the drug along with a nerve block. Their pain levels will be compared to past patients who had standard care. The goal is to see if this comb…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study looks at whether a special cooling cap, called the Amma system, can help women with early-stage breast cancer keep more of their hair during chemotherapy. Fifteen women will use the cap during each chemo session and answer questions about how satisfied they are. The go…

This study explores whether music therapy can reduce anxiety, fatigue, and other symptoms in women with breast cancer who are receiving chemotherapy. Twenty-four participants will take part in weekly group music sessions and use personalized playlists at home, alternating periods…

This study develops and tests a mobile app to help breast cancer and rare cancer survivors manage their fear of the cancer coming back. About 252 participants will try one of three app versions to see which is most helpful and easy to use. The goal is to create a personalized too…

This study tests a portable scalp cooling system called Amma to see if it can prevent hair loss in women receiving chemotherapy for early-stage breast cancer. Forty women with stage I-III breast cancer will use the cooling cap during their chemo sessions. The goal is to see if mo…

This study tests whether acupuncture can improve thinking problems (like memory and focus) in breast cancer survivors. About 270 women who have finished cancer treatment will receive either real acupuncture, sham acupuncture, or standard care. Researchers will track their cogniti…

This pilot study aims to see if doctors can consistently measure paclitaxel levels in the blood of cancer patients receiving the drug. The goal is to eventually adjust doses to give enough chemo to fight cancer while reducing the common side effect of nerve damage. The study invo…

This phase II trial, called MATCH, is testing whether treating cancer based on the genetic makeup of a patient's tumor works better than standard treatments. Over 6,400 adults with advanced solid tumors, lymphomas, or multiple myeloma that have not responded to prior therapy are …

This study follows over 64,000 adults who grew up on farms to see if early exposure to pesticides and other agricultural factors is linked to cancer. Participants fill out an online questionnaire and may provide biological samples. Researchers will track their health over many ye…

This study was designed to see if a combination of PET and MRI scans could detect early signs that treatment is working in people with stage IV HER2-positive breast cancer. The plan was to scan participants up to three times over six months and compare the images to standard meas…

This study tests whether a new type of adaptive radiotherapy can reduce radiation exposure to the ovaries in young women (ages 18-50) receiving pelvic radiation for cancers like uterine, rectal, or cervical cancer. Using advanced imaging and an AI treatment planning system, resea…

This study looks at whether a fermented wheat germ supplement can help the immune system fight cancer better when taken with standard immunotherapy drugs. About 100 adults with advanced solid tumors (like lung, colon, or melanoma) will take the supplement alongside their usual tr…

This study investigates whether early changes on a PET scan can predict which patients with HER2-positive breast cancer will have a complete response to a combination of trastuzumab and pertuzumab given before surgery. Participants receive the two drugs and undergo PET scans at t…

This study tests a special PET scan (FES) that tracks estrogen receptors in breast cancer tumors. Researchers want to see if changes in scan results before, during, and after hormone therapy can show how well the treatment is working. The study involves adults with estrogen recep…

This pilot study is testing whether it's possible to run a larger study that focuses on heart disease in women. Researchers will gather information from 176 women aged 25-55 in Ontario who have had certain female-specific health issues like pre-eclampsia, gestational diabetes, or…

This study looks at how breast cancer treatment affects quality of life in women of different ages. Researchers are asking 650 women recently diagnosed with early-stage breast cancer to fill out questionnaires about their physical and emotional well-being. The goal is to understa…

This study collects blood, urine, and tumor tissue from 500 adults with breast, ovarian, or uterine cancer, plus some of their relatives. The goal is to create a repository of samples for future research on DNA changes that drive these cancers. Participants give samples during ro…

The PRECISION trial is studying whether women with a specific type of early-stage breast cancer can safely avoid radiation therapy after having a lumpectomy. Participants have tumors that are small, hormone receptor-positive, HER2-negative, and low-grade. A gene test called Prosi…

This study follows 810 young women aged 18-45 with early-stage breast cancer to understand how treatment affects their menstrual cycles and quality of life. Participants complete questionnaires every six months for up to 42 months. The goal is to identify factors that lead to ear…

This study looks back at 1,400 women who had breast-conserving surgery for non-palpable breast lesions. It compares two methods used to find the lesion during surgery: injecting a radioactive substance (ROLL) or placing a tiny magnetic seed. The goal is to see which technique lea…

This study was designed to see if a blood test that looks for tiny pieces of tumor DNA (called ctDNA) could find leftover cancer cells in people with early-stage breast cancer after standard treatment. The goal was to help doctors decide who might need more therapy. However, the …

This long-running study follows nearly 100,000 French women, mostly teachers, since 1990 to understand what factors influence their risk of cancer, heart disease, diabetes, and other major illnesses. Participants fill out questionnaires every few years about their lifestyle, medi…

This phase 2 trial is testing whether a special type of PET/CT scan (FDG-PET/CT) can better measure how breast cancer that has spread to the bones responds to treatment. The study involves 138 participants with hormone receptor-positive metastatic breast cancer that is mostly in …

This study tests new ways to help rural primary care clinics provide better follow-up care for cancer survivors. Researchers will give clinics telementoring, quality improvement coaching, and an obesity management toolkit. The goal is to see if these tools help clinics follow nat…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study was designed to see how accurately patients report their own medication and healthcare use in diaries compared to official health insurance records. It planned to include people with diabetes, arthritis, kidney disease, or prostate cancer. However, the study was withdr…

This study looks at how radiation therapy for breast cancer affects tumor DNA and immune cells in the blood. Researchers will track these markers in 217 patients to see if they can predict treatment response. The goal is to use this information to customize radiation plans in the…

This observational study tracks how doctors treat advanced triple-negative breast cancer in Canada, the UK, France, and Spain. Researchers will look at real-world data from 760 patients to understand treatment patterns and outcomes. No new drugs are being tested—the goal is to ga…

This study checks the eye health of people with breast cancer using standard tests like vision charts, eye exams, and scans. The goal is to spot any vision changes or eye damage that might happen during cancer treatment. About 160 participants will be followed to understand how b…

This study tests five different reminder strategies to encourage women in Singapore who are overdue for mammograms to get screened. About 12,750 women aged 50-69 who have not had a mammogram in over two years will receive reminders by mail, with some getting a pre-scheduled appoi…

This study asks 12 clinicians in Florida who care for women with breast cancer about gaps in emotional and mental health support. They will join virtual focus groups and fill out a short survey. The goal is to use their insights to build an AI-powered digital platform called Mamm…

This study looks at how to best collect information about social and behavioral needs (like housing, food, or transportation) from women newly diagnosed with breast cancer. Researchers will compare different screening tools and methods (like chatbots or phone calls) to see which …

This study looks at how different breast cancer treatment decisions, like choosing between a lumpectomy or mastectomy, affect women's quality of life and emotional distress. Researchers followed 345 women with early-stage breast cancer and their partners to measure cancer-related…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at whether regular blood tests can detect changes in stage IV breast cancer during treatment. Researchers will collect blood samples from 150 adults with metastatic breast cancer and analyze them for tumor DNA. The goal is to see if these tests can spot when the …

This study collects white blood cells and tumor cells from cancer patients, and white blood cells from healthy volunteers, to help researchers grow anti-cancer cells in the lab. The goal is to create experimental cell therapies for future use. Up to 7,000 participants will provid…

This study at Johns Hopkins is testing whether genetic information from a blood sample can match what is found in a tumor biopsy for people with metastatic breast cancer. Researchers will use the results to suggest personalized treatment options. The goal is to see if a simple bl…

This study looks at genetic changes in blood and tumor samples from women with advanced hormone receptor-positive, HER2-negative breast cancer who are being treated with palbociclib and endocrine therapy. By comparing genetic material from the cancer tissue with that found in the…

This study aims to find out why some cancer patients develop nerve damage (tingling or numbness in hands and feet) from taxane chemotherapy. Researchers will track over 1,300 people with breast, lung, or ovarian cancer to see how age, gender, and other factors affect their risk. …

This study analyzed stored tumor samples and medical records from nearly 1,900 Greek women who had surgery for early breast cancer. Researchers looked at genetic changes and protein markers in the tumors to see how they relate to breast cancer subtypes and long-term survival. The…

This study follows over 3,600 women who received MemoryShape or MemoryGel breast implants for augmentation or reconstruction. Researchers track complications like rupture, connective tissue disease, and cancer over 10 years. The goal is to gather real-world safety data, not to te…

This study looks at how age changes the way the body handles a breast cancer drug called nab-paclitaxel. Researchers are studying 40 people with metastatic breast cancer to see if older patients process the drug differently. The goal is to make chemotherapy safer and more effecti…

This study tests whether a computer algorithm called ENLIGHT can help find better drug matches for people with advanced breast cancer that has stopped responding to standard treatments. About 175 adults with triple-negative or hormone-resistant breast cancer will have their tumor…

This study collects blood and tissue samples from 300 people with breast cancer that has spread or come back. The goal is to create a large research registry that helps doctors understand why tumors spread and why people respond differently to treatments. Participants provide sam…

This study looks at attention and memory in breast cancer survivors compared to healthy women of the same age. Researchers use EEG to measure brain activity during memory tasks. The goal is to understand why some survivors have trouble focusing or remembering. Results may help de…

This study follows 202 postmenopausal women with early-stage, hormone-sensitive breast cancer who choose to skip radiation after lumpectomy and take only hormone therapy. Researchers track cancer recurrence over 10 years to see if this approach is safe for this low-risk group. Th…

This study looks at how doctors currently diagnose lung and breast cancer using tissue samples. It will also test whether artificial intelligence (AI) can help analyze these samples faster and more accurately. Researchers will review records from 600 patients to measure diagnosis…

This study looks at how the activity of an enzyme called DPD influences how well the chemotherapy drug capecitabine works in women with metastatic breast cancer. Researchers will measure DPD activity before treatment and track tumor response over 24 months. The goal is to see if …

This study tests whether an AI system can create safe and effective exercise plans for women recovering from breast cancer surgery. Researchers will compare the AI's plans to those made by doctors. The goal is to make rehabilitation more personalized and accessible.

This study looks at why some women with breast cancer in one breast later develop cancer in the other breast. Researchers are comparing women with cancer in both breasts to those with cancer in only one breast. They are studying how genes, past radiation treatment, and lifestyle …

This study examines whether medications given during mastectomy to keep blood pressure stable might affect the risk of breast cancer coming back. Researchers will review the records of 250 patients who had mastectomy over five years. They will look at which drugs were used and tr…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study follows 450 premenopausal women with early-stage hormone-positive breast cancer in Italy. Researchers want to see how adding triptorelin to standard hormone therapy affects quality of life and hormone levels. The goal is to better understand the real-world impact of tr…

This study looks at how breast cancer treatment impacts women's jobs, finances, and daily life, especially comparing women from different ethnic groups. About 935 breast cancer survivors who were working before or during treatment will share their experiences. The goal is to unde…

This study uses a special ultrasound technique to monitor blood flow in the breast skin of women who have had a mastectomy and radiation therapy. Researchers want to see how fat grafting affects blood supply. Fifteen women who are already scheduled for breast reconstruction will …

This pilot study aimed to test a new breast-dedicated PET camera that can see details as small as 1 millimeter. Researchers planned to inject a radioactive tracer into people with breast cancer and see if the camera could produce clear images. However, the study was withdrawn bef…

This study tests a web-based tool called gp-multitool.de that helps general practitioners follow guidelines for older patients with multiple chronic conditions. About 659 patients from GP practices in Germany are taking part. The tool lets patients fill out questionnaires online …

This study looks at how three common breast cancer drugs (abemaciclib, ribociclib, or palbociclib) change body fat and muscle in 30 people with ER+/HER2- breast cancer that has spread. Participants get CT and DEXA scans before and after 24 weeks of treatment. The goal is to under…

This study is testing a new lab test called the RNA Disruption Assay (RDA) to see if it can tell how well breast cancer is responding to chemotherapy. Researchers will take small tissue samples (biopsies) from the tumor at specific times during treatment and analyze them. The goa…

This study involves 15 postmenopausal women with metastatic ER+ breast cancer. Researchers are testing a special PET scan that uses a radioactive tracer to see estrogen receptors on tumors. The goal is to find the best way to measure these receptors, which could help doctors know…

This study tests whether AI-generated messages can change how cancer survivors think about alcohol and cancer risk. About 850 adults who have had certain cancers and currently drink alcohol will view different messages. Researchers will measure changes in their beliefs about canc…

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study is testing whether people with cancer or diabetes can use a Fitbit and a continuous glucose monitor (CGM) to track their daily exercise and glucose levels. The goal is to see if it's practical and if people will stick with it. Thirty-five participants will wear both de…

This study looks at why some women disagree with their personal breast cancer risk estimate during mammography screening. Researchers will ask 726 women aged 39-74 about their risk number and whether they want more screening information. The goal is to understand this rejection t…

This study looks at whether it is safe to have an MRI scan when you have breast tissue expanders in place. About 68 people with these expanders will be scanned, and researchers will check for any burning, heating, or pain. The goal is to see if MRI can be done safely in this grou…

The FATLAS study is looking at how body fat (adiposity) influences breast cancer at both the whole-body and cellular levels. Researchers will enroll 150 breast cancer patients with different body types (lean, overweight, obese) and collect blood, tumor tissue, and body measuremen…

This study is for people with HER2-positive metastatic breast cancer who have had a lasting response (complete or partial remission for over 2 years) on anti-HER2 therapy. Researchers will use a personalized blood test called Signatera to look for tiny amounts of cancer DNA. The …

This study looks back at nearly 3,000 women with early-stage invasive breast cancer to see if routine blood test results, along with tumor details, can help predict how the disease will progress. Researchers will track cancer recurrence and survival over time. The goal is to find…

This study looks at how the spread of breast cancer to lymph nodes under the arm relates to long-term outcomes. Researchers are following 2,467 patients to see if certain patterns of lymph node involvement are linked to cancer returning or survival. The goal is to better understa…

This study looks at whether certain genes make African American women with breast cancer more likely to develop nerve damage (pain, numbness, tingling) from common chemotherapy drugs called taxanes. About 249 women with stage I-III breast cancer will receive either docetaxel or w…

This research study collects tissue, blood, and other samples from 2,400 people diagnosed with breast, colon, kidney, liver, multiple myeloma, or prostate cancer at a young age. The goal is to identify genetic changes that may explain why these cancers occur early, especially in …

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study creates a long-term repository of blood, tissue, and health information from 810 people with breast cancer, benign breast disease, or no breast issues. The goal is to provide researchers with resources to better understand breast cancer. No treatment or experimental th…

This study looks at whether the small white moons at the base of fingernails (lunula) can predict how well breast cancer patients respond to chemotherapy before surgery. Researchers will track 188 patients to see if lunula status is linked to tumor disappearance and side effects.…

This study reviews medical records from 300 cancer patients to see if the makeup of a tumor's surroundings (the tumor microenvironment) is linked to how well antibody-based therapies work. Researchers will analyze tissue samples and blood markers from patients with seven types of…

This study looks at 625 people in Russia with high-risk early-stage breast cancer that is HER2-negative. Researchers want to find out how many have BRCA1 or BRCA2 gene mutations and what treatments they receive in real-world practice. Participants provide blood and tumor samples …

This study looks at whether people with HER2-positive breast cancer can safely have fewer heart check-ups while on a specific type of treatment (trastuzumab without anthracyclines). About 190 participants will be followed to see if less monitoring leads to serious heart problems.…

This study collects tissue and blood samples from 1,600 people with various advanced cancers, along with their medical information, over the course of their treatment. Researchers will store these samples and data in a biobank for current and future studies. The goal is to better…

This study looks at why women in the Hauts-de-France region of France may wait longer to start breast cancer treatment, even though they get cancer at similar rates as elsewhere. Researchers will track 500 women from their first symptom to their first treatment, breaking down del…

This study is a registry that tracks side effects and outcomes in people who have undergone cryoablation (freezing) for early stage breast cancer. It is not testing a new treatment but rather collecting real-world data on symptoms, complications, and follow-up results. Only 2 par…

This study collects medical information and tumor samples from 200 men with breast cancer to better understand the disease. Researchers will analyze patient characteristics, treatments, and outcomes over time. The goal is to learn more about male breast cancer, which is rare and …

This study is testing a new way to take MRI images of the breast using a very low magnetic field. The goal is to see if this method can produce clearer pictures of breast cancer. About 40 women with benign or malignant breast tumors will be scanned, and the results will be compar…

This study tests a new program to help breast cancer patients return to work after treatment. It includes 16 working-age women who have work difficulties. The program offers meetings and support from a team of specialists. The goal is to see if this approach is practical and help…

This study looks at whether giving doctors a patient's genetic information can help them personalize chemotherapy doses and reduce serious side effects. About 860 adults with certain cancers (like breast, stomach, or head and neck) will be randomly assigned to have their doctors …

This study tests a program to improve follow-up care for breast cancer survivors in primary care clinics. The program includes training, expert advice, and feedback for clinic staff. Researchers will see if it helps clinics provide more complete care for managing symptoms and lon…

This study looks at 80 women having breast cancer surgery to see if using a mix of two numbing medicines (levobupivacaine and lidocaine) for a nerve block causes more changes in blood pressure and heart rate than using just one (levobupivacaine alone). The goal is to find which a…

This study looks at how women aged 65 and older with early-stage breast cancer decide whether to have chemotherapy before or after surgery. Researchers will use surveys to understand their needs and then create a tool to help patients and doctors make better, shared decisions. Th…

This study looks at whether a physical exercise program can prevent heart damage in breast cancer patients receiving a type of chemotherapy called anthracycline. About 70 participants will be randomly assigned to exercise or usual care. Researchers will use heart scans and blood …

This study looks at whether two different health programs are practical and acceptable for women who have finished treatment for early-stage breast cancer. One program combines nutrition advice, lifestyle changes, yoga, and therapeutic touch (Ayurveda). The other is a self-guided…

This study looks at whether artificial intelligence (AI) can help radiologists find breast cancer earlier when reading mammograms. Researchers will review past mammograms from 785 women, some with breast cancer and some without, to compare how well doctors detect cancer with and …

This study looks back at medical records of 1,950 breast cancer patients to build a tool that predicts whether lymph nodes are cancer-free after chemotherapy. The goal is to identify patients who could safely have a less invasive sentinel node biopsy instead of full lymph node re…

This study enrolls 4,000 people with breast, ovarian, or colorectal cancer to test a comprehensive genetic panel. The panel looks for inherited cancer risks and tumor mutations that may affect drug sensitivity. Researchers aim to validate these genetic findings to potentially gui…

This study tracks over 1,400 breast cancer and lymphoma patients to see how chemotherapy affects memory, attention, and thinking skills. Researchers test patients before, right after, and up to years after treatment. The goal is to learn who is most at risk for 'chemo brain' and …

This study tests a decision aid website called Pathways to Fertility for women newly diagnosed with cancer who may face infertility from treatment. About 130 women will use the website or receive standard care to see if it helps them make more informed and less conflicted decisio…

This study looks at whether combining breast MRI with blood and tissue samples can help find early signs of breast cancer in high-risk women. About 344 women will undergo standard screening MRI and donate leftover tissue and blood. The goal is to better understand how normal brea…

This study examines how genetic variations (SNPs) in certain genes influence how well the drug raloxifene works and its side effects in 600 patients with lobular carcinoma in situ (LCIS), a high-risk breast condition. Participants take raloxifene daily, and researchers sequence t…

This study is watching nearly 3,000 people newly diagnosed with breast cancer in Latin America. It does not test a new treatment but instead collects information on how the cancer is diagnosed, what treatments are used, and how patients do over time. The goal is to better underst…

This study tests a new imaging tool called HyperSight that takes clearer, faster pictures during radiation therapy for cancers of the head/neck, breast, lungs, upper GI, or pelvis. The goal is to see if these images are good enough to help doctors plan treatment more precisely, p…

This early-phase trial is testing whether two advanced imaging techniques—DCE-MRI and molecular breast imaging (MBI)—can accurately assess how triple-negative breast cancer tumors respond to chemotherapy. About 96 patients will undergo these scans before, during, and after treatm…

This observational study looks at how diet, activity, and lifestyle factors relate to muscle strength and heart health in 14 postmenopausal breast cancer patients who received anthracycline chemotherapy. Researchers will measure changes in heart function, muscle energy, and blood…